Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zinc oxide and avobenzone are active ingredients used in sunscreens to protect the skin from the harmful effects of ultraviolet (UV) radiation. Zinc oxide is an inorganic mineral that provides broad-spectrum protection by reflecting and scattering both UVA and UVB rays. Avobenzone is an organic compound that specifically absorbs UVA radiation, the primary cause of long-term skin damage and photoaging. In a Phase 1 clinical trial conducted by the University of California, Davis (NCT01410227), these agents were studied to quantify their effectiveness in reducing the production of singlet oxygen—a reactive oxygen species—in human skin following UVA exposure. This research is critical for understanding how different sunscreen filters mitigate oxidative stress and prevent sun-induced skin damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zinc oxide + avobenzone.